Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Medicine 13, 1269 (1 November 2007) | doi:10.1038/nm1107-1269;
New law gives FDA more influence to monitor drug safety
Abstract
When the US Food and Drug Administration (FDA) announced on 16 October that the diabetes drug Byetta may cause pancreatitis, a serious and sometimes fatal side effect, most scientists could have been forgiven for being taken by surprise. There's not a whiff of pancreatitis in the detailed results from the 19 clinical trials of Byetta in two publicly available databases—one launched and maintained by the drug industry and another by Eli Lilly, which, together with Amylin Pharmaceuticals, markets Byetta.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
